Continually Updated Clinical Reference
 
 
  All Sources     eMedicine     Medscape     Drug Reference     MEDLINE
 
eMedicine - Hydrocele, Filarial : Article by

Quick Find
Authors & Editors
Introduction
Indications
Contraindications
Workup
Treatment
Complications
Outcome And Prognosis
Future And Controversies
Multimedia
References




Patient Education
Click here for patient education.



Author: Bradley Fields Schwartz, DO, FACS, Associate Professor of Urology, Director, Center for Laparoscopy and Endourology, Department of Surgery, Southern Illinois University School of Medicine

Bradley Fields Schwartz is a member of the following medical societies: American College of Surgeons, American Urological Association, Association of Military Osteopathic Physicians and Surgeons, Endourological Society, Society of Laparoendoscopic Surgeons, and Society of University Urologists

Coauthor(s): Joe Miller, MD, Staff Physician, Division of Urology, Southern Illinois University Affiliated Hospitals; Rizk El-Galley, MD, Director of Clinical Research, Assistant Professor, Department of Surgery, Division of Urology, University of Alabama

Editors: Edmund S Sabanegh, MD, Assistant Professor of Urology, Uniformed Services of the Health Sciences; Chier, Section of Male Infertility, Glickman Urological Institute, Cleveland Clinic Foundation; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; J Stuart Wolf, Jr, MD, FACS, David A Bloom Professor of Urology, Director, Division of Minimally Invasive Urology, Department of Urology, University of Michigan Medical Center; Edward David Kim, MD, FACS, Professor of Surgery, Division of Urology, University of Tennessee Graduate School of Medicine; Consulting Staff, University of Tennessee Medical Center

Author and Editor Disclosure

Synonyms and related keywords: filarial hydrocele, scrotal lymphedema, filarial worms, filaria, filariae, Filaria bancrofti, F bancrofti, Wuchereria bancrofti, W bancrofti, Brugia malayi, B malayi, Filaria malaya, F malaya, Culex pipiens, C pipiens, parasitic disease, parasitemia, parasite infection, filariasis, mosquito bite, lymphatic filariasis, nematode, roundworm, round worm, lymphangiectasia, filarial infestation, scrotal filarial infestation, skin sclerosis, elephantiasis, tropical eosinophilia, eosinophilic interstitial pneumonitis, chyluria, bancroftian filariasis, acute filarial lymphangitis, AFL, filarial dance sign, FDS

Lymphatic filariasis is a parasitic disease caused by the nematodes Wuchereria bancrofti, Brugia malayi, and Brugia timori. The adult worms of the species W bancrofti have a predilection for the intrascrotal lymphatic vessels in hosts; thus, hydrocele is the most common manifestation of bancroftian filariasis. In endemic areas, filarial hydrocele is a major cause of disability and disfigurement, as well as a source of direct and indirect economic loss, social stigma, family discord, and sexual burden.

History of the Procedure

Filariasis has been a known disease for thousands of years. The first documentation of this disease was found in Egyptian papyrus prior to 5000 BC. In 1900, Sir Ronald Ross, a scientist from the Liverpool School of Tropical Medicine, reported that lymphatic filariasis is transmitted through mosquito bites. In 1902, Sir Ross was awarded the Nobel Prize in medicine for his discovery that malaria is transmitted to humans through mosquito bites.

Problem

According to World Health Organization (WHO) statistics, 1 billion people in more than 80 countries are at risk for infection with this parasite. More than 120 million people have been affected by the parasites, and more than 40 million of them are seriously incapacitated and disfigured as a result. One third of infected people live in India, one third live in Africa, and most of the remaining affected people live in Asia, islands in the Pacific Ocean, and the Americas. The prevalence of the infection continues to increase in endemic areas.

Frequency

United States

Bancroftian filariasis is endemic in tropical regions throughout the world. In the United States, the disease may be seen in immigrants from these regions and has been reported in military personnel returning from extended deployment to these areas.

International

The WHO estimates that more than 1.3 billion people in 83 countries and territories are at risk for microfilarial infection. More than 90% of the estimated 120 million infections are due to W bancrofti, of which 26.79 million cases are hydrocele. India bears the greatest burden of this disease, with more than 550 million people at risk. Other endemic areas include the countries of sub-Saharan Africa and Southeast Asia, areas of Latin America, and the Pacific Islands. Prevalence rates of lymphatic filariasis and filarial hydrocele vary. A sample of nearly 5,000 people from 37 districts in Nepal reported a lymphatic filariasis prevalence of up to 40%.1 A similar study of migrant workers in Myanmar found a prevalence of 2.4%. In endemic countries of Asia and Africa, the prevalence of filarial hydrocele in men older than 45 years commonly exceeds 50%.

Race

No racial predilection for filarial infection has been shown.

Sex

The sexual prevalence of filarial infection varies by region, possibly because of variable exposure in cultural or employment patterns that result in contact with vector species of mosquito.

Age

All ages are susceptible to microfilarial infection. Clinical manifestation and acute presentations of lymphatic filariasis increase in prevalence with age. The prevalence of filarial hydrocele also increases with age.

Etiology

Eight main species of nematodes (roundworms) can cause filariasis; however, the most common is W bancrofti (100 X 0.3 mm), followed by Brugia organisms. The nematodes can live for several years in the lymphatic vessels and lymph nodes. The female worms produce microfilariae (200-300 µm), which circulate in the blood. The microfilariae infect biting Culex pipiens mosquitoes (less commonly Anopheles, Aedes, and Mansonella species). It then develops into the infective filariform larvae within 1-2 weeks. During subsequent bites by the mosquito, the larvae infect human hosts and migrate to the lymphatic tissues, where they develop into adult worms within a year.

Pathophysiology

Humans are the definitive host of W bancrofti. Numerous species of mosquitoes from the genera Anopheles, Culex, Aedes, and Mansonia serve as the intermediate host. In infected humans, the adult W bancrofti worms are most commonly found in periaortic, inguinal, and intrascrotal lymphatic tissue.

The microfilariae produced by the female worms enter the bloodstream and are ingested by feeding mosquitoes. Once in the mosquito, the juvenile worms pass through 2 larval stages before development halts. Subsequent blood meals taken by the mosquitoes transmit the third-stage larvae into the human dermis. The juvenile worms then migrate to lymphatic tissue in the infected human, where maturation is completed.

While the adult female worms can continue to produce microfilariae in the human host, the adult worm burden cannot increase in the absence of the intermediate host. In endemic areas, filarial infection begins in childhood and the adult worm burden increases upon repeated exposures. Acute presentations most commonly occur in the fourth or fifth decade of life.

Death of the adult worm causes an inflammatory reaction that manifests as acute filarial lymphangitis (AFL). Granulomatous nodule formation and recurrent episodes of AFL impair lymphatic flow, which predisposes the host to secondary bacterial infections. Secondary bacterial infections result in fibrosis, lymphatic obstruction, and lymphedema. High-protein lymphedema causes further inflammation and tissue destruction. Once damage is sufficient to overwhelm the lymphatic system, chronic hydrocele results.

Recent research has implicated the endosymbiotic bacteria Wolbachia as a possible trigger in the immune reaction following the death of adult worms.2, 3 Release of these obligate intracellular bacteria by the dead adult W bancrofti worm increases the host’s plasma levels of interleukin (IL)–6, IL-10, lipopolysaccharide-binding protein (LBP), and soluble tumor necrosis factor (TNF)–alpha receptors. The exact role of Wolbachia in lymphatic filariasis and the possibility of novel targets for prevention and treatment, including tetracycline antibiotics, have not been fully studied.

Clinical

Although filarial infection in endemic areas is generally acquired in childhood, the disease may take years to manifest before being diagnosed clinically in early adulthood. Therefore, in endemic areas, up to 50% of the population (more commonly men) may have subclinical infection and may develop pathologic sequelae (although rare). This is characterized by the presence of thousands or millions of parasites in the blood. However, this small number of infections in endemic areas with pathologic changes accounts for the bulk of clinical disease.

Many individuals with filarial infection develop fever due to immune reactions. Patients present with episodic fever associated with lymphangitis, lymphadenitis, funiculoepididymitis (ie, inflammation of the spermatic cord and epididymis), transient edema, and small hydroceles. Patients with secondary infections may also present with fever and a purulent reaction.

The hallmark of clinical disease is lymphedema. Patients in the prepatent period (50-150 d) may develop acute lymphedema of the scrotum that remits spontaneously or after medical treatment. In these patients, lymphatic tissues show typical changes of filarial infection, but adult worms are rarely found.

In contrast, patients with established infections develop permanent lymphatic scarring, which results in progressive lymphedema. The genitals and lower extremities are the areas most commonly affected.

Elephantiasis of the penis and scrotum in patients with filariasis is the most common clinical problem encountered by urologists. Secondary bacterial infections of the skin and local lymph nodes are common in these patients. Although bacteria play no role in chyluria or filarial hydrocele, elephantiasis and lymph scrotum are often superinfected. Bacterial or fungal infections (most commonly streptococci) lead to recurrent lymphangitis, erysipelas, chronic ulcers, or persistent fungal crusting, aggravating the clinical conditions.

Chyluria develops before elephantiasis in young adult patients. Chyluria results from obstruction of the retroperitoneal lymphatic channels, which leads to dilatation and rupture in the urinary collecting system. Initially, chyluria may alarm patients; however, subsequently, it may be disregarded. Occasionally, urinary protein loss may be significant and may lead to hypoalbuminemia and anasarca. Most cases of chyluria are intermittent and respond to bed rest and abdominal binders to increase intra-abdominal pressure. Retrograde lymphangiography and lymphosclerosis can be used in an attempt to treat persistent cases.

Filarial hydroceles vary significantly in size. They can grow very large and may become socially unacceptable and cause significant morbidity and discomfort. Differentiating filarial hydrocele from idiopathic hydrocele is difficult in many cases. A history of exposure to infection from traveling to or residency in endemic areas is suggestive. The patient should be examined for other manifestations of filariasis. Patients with filarial hydroceles often have a thickened spermatic cord and epididymis with firm nodules. During surgery, the tunica is thickened with calcifications in the wall, and the hydrocele fluid is milky. These findings are uncommon in patients with uncomplicated idiopathic hydroceles. Microfilariae and adult worms are rarely detected in hydrocele fluid.



Contrary to the conclusions in previous literature, a recent double-blind study in Tanzania found that medical treatment with diethylcarbamazine (DEC) does not affect hydrocele size. Surgery is the treatment of choice for filarial hydrocele.

Indications for hydrocele surgery include the following:

  • Medical ineligibility due to untreated hydroceles
  • Interference with work
  • Interference with sexual function
  • Interference with micturition
  • Negative impact on the patient's family
  • Dragging pain
  • Susceptibility to trauma because of the patient's work or mode of transport
  • Possible effect on the testis of long-standing hydroceles



Because of the scarcity of information regarding surgical treatment of filarial hydrocele, clear contraindications have not been elucidated. Standard contraindications to surgical procedures probably apply.



Lab Studies

  • CBC count: Patients with patent filarial infection commonly have marked eosinophilia.
  • Serum immunoglobulins: Elevated serum levels of immunoglobulin E (IgE) and immunoglobulin G4 (IgG4) are seen with microfilarial infection.
  • Circulating filarial antigen: Commercial tests to detect circulating filarial antigen (CFA) using monoclonal antibodies (mAb Og4C3 or mAb AD.12) are widely available.
  • Hydrocele fluid examination: CFA may be detected in hydrocele fluid and microfilariae may be found on cytology.
  • Urine examination: Chyluria may be detected macroscopically and microfilariae may be detected via microscopic examination of voided urine. Proteinuria and hematuria may also be seen with microfilarial infection with renal involvement.
  • Peripheral blood examination: Microfilariae may be detected via microscopic examination of peripheral blood. Microfilariae demonstrate a circadian pattern that varies by endemic region, necessitating serum sampling that coincides with periods of activity. Activity may be provoked with administration of DEC.

Imaging Studies

Ultrasonography: Lymphatic obstruction can be demonstrated on ultrasonography. Motile adult worms may be seen in symptomatic and subclinical filarial hydroceles. The characteristic movements of adult filarial worms are called the filarial dance sign (FDS) and are a reliable diagnostic finding. Ultrasonography may also be used to monitor response to treatment.



Medical therapy

In 1997, the World Health Assembly (WHA) passed a resolution calling for the initiation of lymphatic filariasis–elimination programs by the governments of endemic areas. As of 2005, the Global Programme to Eliminate Lymphatic Filariasis (GPELF) has reached nearly 50% of the at-risk world population with mass drug administration of the 2-drug regimens (DEC plus albendazole or ivermectin plus albendazole) or administration of DEC-fortified salt. Epidemiological studies indicate that several countries have demonstrated a near-total absence of transmissions as a result of mass drug administration. Programs aimed at alleviating and preventing disability from lymphatic filariasis are also underway.

Subclinical cases should be treated to prevent lymphatic damage because most patients develop full clinical disease. Young adults in endemic areas should be screened for the presence of the parasite and treated if test results are positive.

  • DEC is effective against both microfilariae and adult worms and is considered the drug of choice. It clears the blood of microfilariae, reduces the opportunity for mosquito-borne transmission of the parasite, and reverses filarial-associated hematuria and proteinuria.
    • DEC does not reverse existing lymphatic damage and does not change the course of pathology in patients with established disease. Patients should be tested every 6-12 months for the presence of the parasite, and patients whose test results are positive should be re-treated.
    • DEC is only partially effective against adult worms; therefore, ultrasonography of the scrotum 1 month after treatment shows any residual worms, which is an indication for re-treatment.
    • Recommended schedules are 6 mg/kg/d for a total of 72 mg/kg for W bancrofti infection and 4 mg/kg/d for a total of 60 mg/kg for infection with B malayi.
    • DEC causes allergic reactions (Mazzotti reactions), especially in patients with high microfilarial counts. Headache, fever, nausea, vomiting, local pain, and swelling over lymph nodes and along lymphatic vessels have been reported. Therefore, patients with heavy infection should start with low doses (3 mg/kg body weight/d) and gradually increase the dose.
  • Ivermectin is a newer antiparasitic drug that causes fewer adverse effects. It has proven to be an effective microfilaricide after a single oral dose of 20-25 mcg/kg of body weight. Because of its low cost, single oral dose, and few adverse effects, it is becoming the drug of choice for early filarial infection. However, ivermectin does not affect adult filarial worms.
  • Foot care and skin care are essential in patients with lymphedema. Patients should be encouraged to use antiseptic soap to clean their skin daily. Early infections should be treated vigorously.

Surgical therapy

Various surgical procedures have been developed to remove the edematous tissue in patients with genital elephantiasis. The principles of these operations follow general plastic-surgery principles.

  • The penile and scrotal skin and subcutaneous tissues can be excised and reconstructed using a partial-thickness graft from normal skin in the upper part of the body without lymphedema. Unmeshed grafts yield a better cosmetic appearance to the penis, while meshed grafts are preferred for scrotal reconstruction. In females, split-thickness grafts can be used to reconstruct the vulva and the perineal skin.
  • Filarial hydroceles are more difficult to excise surgically than idiopathic hydroceles because of scarring and fibrosis. The ideal procedure is to excise the hydrocele completely with an intact sac. In some cases, this is impossible, and partial excision and eversion of sac edges behind the testis is sufficient.

Preoperative Details

Antibiotics should be initiated the night prior to surgery and continue for a total of 5 days. Analgesics in the form of nonsteroidal anti-inflammatory drugs or oral acetaminophen should be administered as appropriate.

Postoperative Details

Standard postoperative care applies. Most patients may be discharged home the same day. Patients with undue swelling, pain, or oozing from the wound or those in whom a drain has been placed should be observed for 24-48 hours.

Follow-up

Patients should return for a follow-up visit within 7-10 days.



Wound healing is slow and complicated in patients with filariasis because of the lymphedema and chronic scarring. Patients who require excision and grafting of the scrotal or penile skin are at higher risk for graft failure. Wound infections are also common in these patients.



Established filarial lymphedema is a progressive condition that tends to follow a stable course within 10-15 years of clinical presentation. No medical treatment has been proven to reverse this pathology; therefore, early diagnosis and treatment are of utmost importance.



Because of the recent advances in medical treatment with single-dose therapies, global elimination of lymphatic filariasis is now considered possible. To interrupt transmission, districts where lymphatic filariasis is endemic must be identified and community-wide programs must be implemented to treat the entire at-risk population. Community education programs are necessary to raise awareness in affected patients.

In January 1998, the pharmaceutical company SmithKline Beecham (now GlaxoSmithKline) announced a massive donation program of albendazole (several billion doses) to support this effort. This donation was coupled with a decision by Merck & Co, Inc to expand its ongoing ivermectin (Mectizan) donation program to include treatment of lymphatic filariasis.



Media file 1:  Filarial infection causing enlarged pubic lymph nodes.
Click to see larger pictureClick to see detailView Full Size Image
Media type:  Photo

Media file 2:  Laparoscopic view of enlarged lymphatics secondary to filarial infection.
Click to see larger pictureClick to see detailView Full Size Image
Media type:  Photo

Media file 3:  Lymphocele of the right spermatic cord.
Click to see larger pictureClick to see detailView Full Size Image
Media type:  Photo



  1. Sherchand JB, Obsomer V, Thakur GD, Hommel M. Mapping of lymphatic filariasis in Nepal. Filaria J. Mar 19 2003;2(1):7. [Medline].
  2. Lammie PJ, Cuenco KT, Punkosdy GA. The pathogenesis of filarial lymphedema: is it the worm or is it the host?. Ann N Y Acad Sci. Dec 2002;979:131-42; discussion 188-96. [Medline].
  3. Taylor MJ. A new insight into the pathogenesis of filarial disease. Curr Mol Med. May 2002;2(3):299-302. [Medline].
  4. Approaches to the urogenital manifestations of lymphatic filiariasis. Geneva, Switzerland: World Health Organization; 2002.
  5. Bosworth W, Ewert A. The effect of Streptococcus on the persistence of Brugia malayi and on the production of elephantiasis in cats. Int J Parasitol. Dec 1975;5(6):583-9. [Medline].
  6. Cohen LB, Nelson G, Wood AM, Manson-Bahr PE, Bowen R. Lymphangiography in filarial lymphoedema and elephantiasis. Am J Trop Med Hyg. Nov 1961;10:843-8. [Medline].
  7. Dreyer G, Norões J, Figueredo-Silva J, Piessens WF. Pathogenesis of lymphatic disease in bancroftian filariasis: a clinical perspective. Parasitol Today. Dec 2000;16(12):544-8. [Medline].
  8. Eigege A, Richards FO Jr, Blaney DD, Miri ES, Gontor I, Ogah G. Rapid assessment for lymphatic filariasis in central Nigeria: a comparison of the immunochromatographic card test and hydrocele rates in an area of high endemicity. Am J Trop Med Hyg. Jun 2003;68(6):643-6. [Medline].
  9. Hussein O, El Setouhy M, Ahmed ES, Kandil AM, Ramzy RM, Helmy H, et al. Duplex Doppler sonographic assessment of the effects of diethylcarbamazine and albendazole therapy on adult filarial worms and adjacent host tissues in Bancroftian filariasis. Am J Trop Med Hyg. Oct 2004;71(4):471-7. [Medline].
  10. Nielsen NO, Bloch P, Simonsen PE. Lymphatic filariasis-specific immune responses in relation to lymphoedema grade and infection status. I. Cellular responses. Trans R Soc Trop Med Hyg. Jul-Aug 2002;96(4):446-52. [Medline].
  11. Ottesen EA. The human filariases: New understanding, new therapeutic strategies. Curr Opin Infect Dis. 1994;7:550-8.
  12. Ottesen EA, Vijayasekaran V, Kumaraswami V, Perumal Pillai SV, Sadanandam A, Frederick S, et al. A controlled trial of ivermectin and diethylcarbamazine in lymphatic filariasis. N Engl J Med. Apr 19 1990;322(16):1113-7. [Medline].
  13. Tobian AA, Tarongka N, Baisor M, Bockarie M, Kazura JW, King CL. Sensitivity and specificity of ultrasound detection and risk factors for filarial-associated hydroceles. Am J Trop Med Hyg. Jun 2003;68(6):638-42. [Medline].
  14. Weekly epidemiological record. Geneva, Switzerland: World Health Organization; 2006.
  15. Weil GJ, Lammie PJ, Weiss N. The ICT Filariasis Test: A rapid-format antigen test for diagnosis of bancroftian filariasis. Parasitol Today. Oct 1997;13(10):401-4. [Medline].

Hydrocele, Filarial excerpt

Article Last Updated: Dec 27, 2007